Novo Nordisk A/S | NOVOB - Operating Expenses


Novo Nordisk reported DKK46.76B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Bausch Health Companies USD 2.08B 113M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 193.68M 27.32M Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025